CM
MRTX

Crystalline Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Crystalline Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$361K – 134
2023
Q2 		$361K Hold
10,000
– – 0.26% 69
2023
Q1 		$534K Hold
10,000
– – 0.39% 50
2022
Q4 		$453K Buy
+10,000
New +$647K 0.23% 76

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crystalline Management's MRTX Position: Q3 2023 in Review

Crystalline Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 10,000 shares — an estimated $361K sold.

Crystalline Management first reported a position in MRTX in Q4 2022 and held it in 3 quarters. The position peaked at $534K in Q1 2023. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Crystalline Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Crystalline Management sold 10,000 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $361K.
  • Crystalline Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Crystalline Management's Mirati Therapeutics, Inc. Common Stock position peaked at $534K in Q1 2023.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Crystalline Management's 13F filing for Q3 2023, filed 13 Nov 2023.